TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03040349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider and Patient Tools
Description: Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-blast and Webinars
Description: In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.
Study: NCT03872765

Intervention type: DEVICE
Group type: OTHER
Intervention: Laser surgery
Description: Use of CO2 laser to perform surgeries to treat chronic anal fissure
Study: NCT02453256

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab
Description: Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.
Study: NCT04439058

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided left stellate ganglion block
Description: Stellate Ganglion Block (SGB) has several established clinical indications Under complete aseptic precautions an ultrasound guided left stellate ganglion block was performed. (paratracheal technique ) ( ) The patient was placed in the supine position with the head in the neutral position and slightly extended. An initial scanning was done with the ultrasound to identify the structures in this area.~The US probe was placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra was identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia were sought anterior to the C6 vertebral body and deep to the carotid artery. After skin infiltration with local anesthetic, the needle was inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound guided left stellate ganglion block
Description: Stellate Ganglion Block (SGB) has several established clinical indications Under complete aseptic precautions an ultrasound guided left stellate ganglion block was performed. (paratracheal technique ) ( ) The patient was placed in the supine position with the head in the neutral position and slightly extended. An initial scanning was done with the ultrasound to identify the structures in this area.~The US probe was placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra was identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia were sought anterior to the C6 vertebral body and deep to the carotid artery. After skin infiltration with local anesthetic, the needle was inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli
Study: NCT02380963

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colorado Diet with soy protein foods.
Description: Phase 1 (week 1-2): Participants will be given soy protein powder and asked to consume 3 protein shakes per day.~Phase 2 (week 3-8): Participants will be given both protein powder and soy patties designed to be similar to other phase 2 acceptable foods and will be asked to consume 2 soy protein shakes and 1 soy patty per day.~Phase 3 (week 9-16): Participants will be given protein powder, soy patties, and protein bars designed to be similar to other phase 3 acceptable foods and will be asked to consume 1 soy protein shake, 1 soy patty and 1 soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive study food products (protein powder, patties and protein bars)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Colorado Diet with monetary payments
Description: Phase 1 (week 1-2): Participants will be given monetary stipend and asked to consume 3 non-soy protein shakes per day.~Phase 2 (week 3-8): Participants will be given monetary stipends and asked to consume 2 non-soy protein shakes per day.~Phase 3 (week 9-16): Participants will be given monetary stipend and asked to consume 1 non-soy protein shake and 1 non-soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive monetary stipend.
Study: NCT00819481

Intervention type: DEVICE
Intervention: 3DKnee™ System
Description: Total knee replacement joint for subjects with knee osteoarthritis and willing to participate in the study.
Study: NCT01607853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)
Description: Once daily application, 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)
Description: Once daily application, 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® gel applied for 24 hours (+/- 2 hours)
Description: Once daily application, 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)
Description: Once daily application, 3 weeks
Study: NCT03232216

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3.
Description: Vitamin D3 50.000 UI in each packet of powder for oral solution.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3.
Description: Vitamin D3 50.000 UI in each packet of powder for oral solution.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.
Study: NCT02548884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary cannulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary cannulation
Study: NCT02437188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT (Acceptance and Commitment Therapy)
Description: The 1-day training session with ACT proposed for this study is designed to reduce behavioral avoidance and to enhance acceptance-based coping. The intervention includes: 1) Behavioral Change Training (2.5 hours) involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training (2.5 hours) emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts and learning how to willingly face experiences that cannot be changed.
Study: NCT01048944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion SR
Description: 150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch and Placebo Pill
Description: 150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
Study: NCT04974606

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cherry-flavored still beverage
Description: 10 oz bottle

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry-flavored still beverage
Description: 10 oz bottle

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry-flavored still beverage
Description: 10 oz bottle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cherry-flavored still beverage
Description: 10 oz bottle
Study: NCT06005090

Intervention type: PROCEDURE
Intervention: Far Cortical Locking Technique
Description: Apart from the traditional 3 point fixation of the locking screw this technique compromises two point fixation of the screw where one into the plate and the other is into the far cortex of the diaphysis. The near cortex was widened by 3.2 mm of dirll bit to eliminate the fixation of the screw into the near cortex
Study: NCT01421147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously
Study: NCT03439891

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study: NCT03581955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banana Cavendish
Description: 240g of fruit plus 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato
Description: 300g of raw tomato (coeur de boeuf) with refined sunflower oil (12g) and 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresubin ® 2kcal fiber neutral flavor
Description: 250 ml Fresubin ® 2kcal fiber neutral flavor
Study: NCT03315598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: lectroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
Study: NCT02074332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity guidance
Description: Physical education class amelioration Additional physical activities for overweight\&obese students Family physical activities Parent involvement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Knowledge of obesity prevention and control
Study: NCT01469598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Docetaxel
Description: Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
Study: NCT03529799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-PAS Goggles
Description: Portable, head-mounted display goggle system with integrated eye capture technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-PAS Goggles
Description: Portable, head-mounted display goggle system with integrated eye capture technology
Study: NCT04217824

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pilonidal sinus excision
Description: Closure of the defect in pilonidal sinus excision with one of the randomly selected flap methods.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pilonidal sinus excision
Description: Closure of the defect in pilonidal sinus excision with one of the randomly selected flap methods.
Study: NCT03041467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IN.PACT AV DCB
Description: IN.PACT™ AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Balloon Angioplasty
Description: Standard PTA Balloon
Study: NCT00309023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663513
Description: mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
Study: NCT01044992

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: H215O PET
Description: H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.
Study: NCT02173379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Description: * Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE
Description: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Study: NCT00818740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: i.v., oral solution and oral capsule forms. Oral capsule given with and without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: i.v., oral solution and oral capsule forms. Oral capsule given with and without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: i.v., oral solution and oral capsule forms. Oral capsule given with and without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: i.v., oral solution and oral capsule forms. Oral capsule given with and without food.
Study: NCT03545620

Intervention type: DEVICE
Intervention: rescue technique
Description: which rescue technique will be preferred while established/predicted difficult airway/intubation occurs in the operation room after failed direct laryngoscopy
Study: NCT00183833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine, imatinib mesylate
Description: Capecitabine and imatinib mesylate will both be taken by mouth twice a day
Study: NCT02732015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant Dimeglumine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study: NCT01044992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.
Study: NCT04321122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound cyclo plasty
Description: The ultrasonic glaucoma treatment instrument produced by French EYE TECH CARE company is referred to as EyeOP1.It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast.
Study: NCT03220997

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitaflow Preload
Description: Carbohydrate loading drink
Study: NCT02712164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified NPWT dressing
Description: Use of negative pressure wound therapy on split-thickness skin graft (STSG) donor sites

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm
Description: Standard of care for STSG donor sites.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tegaderm
Description: Standard of care for STSG donor sites.
Study: NCT01379456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: exercises, 20 sessions over 10 weeks
Study: NCT02526186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Battlefield Auricular Acupuncture
Study: NCT01884220

Intervention type: OTHER
Intervention: There are no interventions in this study.
Study: NCT02907437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline as an add-on drug (200 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (200 mg/day)
Study: NCT02732015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT00851188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet CBT self-help
Description: Internet based Cognitive behavioral self-help method for insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT self-help booklet
Description: Cognitive behavioral self-help method for insomnia via booklet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Description: Waiting list
Study: NCT01421992

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: One Tablet of methylphenidate, 20 mg per day during 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet placebo per day during 3 weeks
Study: NCT04118179

Intervention type: OTHER
Intervention: Blood sample collection
Description: A blood sample (1 tube) will be collected for the analysis of the CR signature.

Intervention type: OTHER
Intervention: Blood sample collection
Description: A blood sample (1 tube) will be collected for the analysis of the CR signature.
Study: NCT02907437

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: (450 mg/day)
Study: NCT04118179

Intervention type: OTHER
Intervention: Blood sample collection
Description: A blood sample (1 tube) will be collected for the analysis of the CR signature.
Study: NCT03525808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXIOS
Description: Patient will receive either transgastric or transduodenal endoscopic drainage for walled-off necrosis that are adherent to the gastric or bowel wall.